Resveratrol trimer enhances gene delivery to hematopoietic stem cells by reducing antiviral restriction at endosomes
2019
Therapeutic
gene deliveryto hematopoietic stem cells (HSCs) holds great potential as a life-saving treatment for a range of
monogenic, oncologic, and infectious diseases. However, clinical gene therapy is severely limited by intrinsic HSC resistance to modification with lentiviral vectors (LVs), thus requiring high doses or repeat LV administration to achieve therapeutic gene correction. Here we show that temporary co-application of the cyclic resveratrol trimer caraphenol A enhances LV
gene deliveryefficiency to human and non-human primate hematopoietic stem and progenitor cells. While significant ex vivo, this effect was most dramatically observed in human lineages derived from HSCs transplanted into immunodeficient mice. We further demonstrate that caraphenol A relieves restriction of LV transduction by altering the levels of interferon-induced transmembrane (IFITM) proteins IFITM2 and IFITM3 and their association with late
endosomes, thus augmenting LV core
endosomalescape. Caraphenol A-mediated IFITM downregulation did not alter the LV integration pattern or bias lineage differentiation. Taken together, these findings compellingly demonstrate that the pharmacologic modification of
intrinsic immunerestriction factors is a promising and non-toxic approach for improving LV-mediated gene therapy.
Keywords:
-
Correction
-
Source
-
Cite
-
Save
85
References
12
Citations
NaN
KQI